Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Fineline Cube Apr 27, 2026
Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Fineline Cube Apr 27, 2026
Company Deals

Tonghua Dongbao Pharmaceuticals Partners with King-Friend Biochemical on Insulin Development

Fineline Cube Sep 18, 2023

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has entered into a partnership with fellow Chinese firm...

Company Drug

EMA’s CHMP Backs Enhertu for Advanced NSCLC with HER2 Mutations

Fineline Cube Sep 18, 2023

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Deals

BMS Expands Partnership with Samsung Biologics for Oncology Drug Manufacturing

Fineline Cube Sep 18, 2023

Global pharmaceutical company Bristol-Myers Squibb (BMS; NYSE: BMY) has announced an expansion of its existing...

Company Drug

EMA’s CHMP Recommends Approval of Keytruda as Adjuvant NSCLC Treatment

Fineline Cube Sep 18, 2023

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Drug

Novartis’s Kisqali Reduces Cancer Recurrence Risk in HR+/HER2- Early Breast Cancer: Phase III Results

Fineline Cube Sep 18, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has published results from a Phase III study of...

Company

CanSino Biologics Reports H1 2023 Revenues Down 96.7% YOY, COVID-19 Demand Decreases

Fineline Cube Sep 18, 2023

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has released its financial report for the first...

Company Deals R&D

GemPharmatech Partners with Daxiang Biotech to Advance Preclinical Evaluation Models

Fineline Cube Sep 18, 2023

Nanjing-based GemPharmatech Co., Ltd, a center for laboratory animal seed resources and a specialist in...

Company Drug

Akeso Biopharma’s AK132 Receives Green Light for Clinical Trial in Advanced Solid Tumors

Fineline Cube Sep 18, 2023

Akeso Biopharma’s (HKG: 9926) AK132, a bispecific antibody (BsAb) targeting Claudin18.2 and CD47, has received...

Company Medical Device

AcornMed Receives FDA Breakthrough Device Designation for Urothelial Carcinoma Liquid Biopsy

Fineline Cube Sep 18, 2023

Beijing-based tumor precision medicine specialist, AcornMed, has been granted Breakthrough Device Designation (BDD) by the...

Company Deals Digital

Baidu Health Partners with HOB Biotech to Innovate Allergy Detection and Treatment

Fineline Cube Sep 18, 2023

Baidu Health has entered into a strategic partnership with HOB Biotech Group, a leading in...

Company Medical Device

Tuodao Medical’s Percutaneous Puncture Surgery Robot NP100 Approved in China

Fineline Cube Sep 18, 2023

China-based surgical robot developer Tuodao Medical Technology Co., Ltd has received marketing approval for its...

Company Drug

CSPC Pharmaceutical Group Receives NMPA Approval for Irinotecan Liposome Injection

Fineline Cube Sep 18, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received market approval...

Company Medical Device

Jenscare Scientific’s Tricuspid Valve Replacement System Joins FDA’s TAP Program

Fineline Cube Sep 18, 2023

Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced that...

Legal / IP

Jiangsu Hengrui Pharmaceuticals Entangled in Legal Disputes with BeyondSpring and Reistone

Fineline Cube Sep 18, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) is currently entangled in legal challenges involving...

Company

Astellas Pharma Invests EUR 330 Million in State-of-the-Art Manufacturing Plant in Ireland

Fineline Cube Sep 15, 2023

Japanese pharmaceutical company Astellas Pharma (TYO: 4503) has announced a significant investment of EUR 330...

Company Policy / Regulatory

China Launches Fourth National Volume-Based Procurement Tender Focusing on Medical Consumables

Fineline Cube Sep 15, 2023

The national high-value medical consumables joint procurement office has released a notification, marking the commencement...

Company

J&J Rebrands Pharmaceutical and MedTech Segments Post-Kenvue Separation

Fineline Cube Sep 15, 2023

Following the completion of its consumer healthcare unit separation as Kenvue (NYSE: KVUE) last month,...

Company Drug

Japan’s MHLW Reviews GSK’s Momelotinib for Myelofibrosis Treatment

Fineline Cube Sep 15, 2023

The Ministry of Health, Labour and Welfare (MHLW) in Japan has accepted for review a...

Company Drug

AstraZeneca and Daiichi Sankyo Report Positive Results for Datopotamab Deruxtecan Combo in NSCLC

Fineline Cube Sep 15, 2023

UK-based pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced positive data from a Phase Ib...

Company Deals

Sichuan Kelun Pharmaceutical Secures Exclusive Rights to TBM-001 for Bone Metastasis Diagnosis

Fineline Cube Sep 15, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech...

Posts pagination

1 … 463 464 465 … 657

Recent updates

  • Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
  • Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China
  • Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU
  • Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104
  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.